EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Advances in Non-Small Cell Lung Cancer Cellular Immunotherapy: A Progress in Dendritic Cell, T-Cell, and NK Cell Vaccines

Mirza Masroor Ali Beg, Mohammad Aslam, Asma Ayaz iD, Muhammad Saeed Akhtar iD, Wajid Zaman iD

Cells · 2025

DOI: 10.3390/cells14181453 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cells, 2025. Verfasst von Mirza Masroor Ali Beg und 4 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Ala-Too International University, Bishkek 720048, Kyrgyzstan. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Cancer Vaccines, Killer Cells, Natural. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Over the past decade, cellular immunotherapy has emerged as a transformative strategy for non-small cell lung cancer (NSCLC), with dendritic-cell (DC) vaccines, T-cell vaccines, and natural killer (NK)-cell therapies demonstrating distinct mechanisms and clinical potential. DC vaccines capitalize on antigen presentation to prime tumor-specific T-cell responses, showing excellent safety profiles limited mainly to injection-site reactions and flu-like symptoms. While monotherapy has shown limited efficacy, combinations with checkpoint inhibitors or chemotherapy enhance immune activation and survival outcomes. Recent innovations, including neoantigen-loaded, mRNA-electroporated, and exosome-pulsed DCs, demonstrate improved immunogenicity and personalized approaches. T-cell vaccines, designed to activate cytotoxic CD8+ T-cell responses, have been tested across multiple platforms, including peptide-based (MAGE-A3), viral vector (TG4010/MUC1), and mRNA (CV9201/92) formulations. While the phase III MAGRIT trial presented no disease-free survival (DFS) benefit with adjuvant MAGE-A3 vaccination, the TG4010 vaccine improved progression-free survival (PFS; HR 0.66) and overall survival (OS; HR 0.67) in MUC1-positive NSCLC when combined with chemotherapy. Current strategies focus on personalized neoantigen vaccines and KRAS-targeted approaches (e.g., ELI-002), with ongoing phase III trials evaluating their potential in resectable NSCLC. NK-cell therapies have also shown promise, with early trials establishing the feasibility of autologous and allogeneic infusions, while engineered CAR-NK cells enhance tumor-specific targeting. Combination strategies with checkpoint inhibitors significantly improve response rates and PFS, revealing synergies between innate and adaptive immunity. Recent advances include cytokine-enhanced, memory-like NK cells to overcome immunosuppression and “off-the-shelf” products for broader clinical use. Together, these cellular immunotherapies represent a versatile and evolving frontier in NSCLC treatment, with ongoing research optimizing combinations, delivery platforms, and patient selection to maximize therapeutic benefit.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsCancer VaccinesKiller Cells, NaturalDendritic CellsImmunotherapyT-LymphocytesHumansAnimals

Stichwörter der Autor:innen

NK-cell vaccinesT celladverse eventsbiomarkerscell-based immunotherapyclinical outcomescombination therapydendritic cellnon-small cell lung cancersafety

Substanzen

Cancer Vaccines

Autor:innen und Institutionen

  • Faculty of Medicine, Ala-Too International University, Bishkek 720048, Kyrgyzstan.
  • Department of Chemical Engineering, Yeungnam University, Gyeongsan 38541, Republic of Korea.
  • Faculty of Sports Science, Ningbo University, Ningbo 315211, China.
  • Department of Chemistry, Yeungnam University, Gyeongsan 38541, Republic of Korea.
  • Department of Life Sciences, Yeungnam University, Gyeongsan 38541, Republic of Korea.

ORCID-Profile: Asma Ayaz, Muhammad Saeed Akhtar, Wajid Zaman

Zitieren

APA

Masroor Ali Beg, M., Aslam, M., Ayaz, A., Akhtar, M. S., & Zaman, W. (2025). Advances in Non-Small Cell Lung Cancer Cellular Immunotherapy: A Progress in Dendritic Cell, T-Cell, and NK Cell Vaccines. Cells. https://doi.org/10.3390/cells14181453

Vancouver

Masroor Ali Beg M, Aslam M, Ayaz A, Akhtar MS, Zaman W. Advances in Non-Small Cell Lung Cancer Cellular Immunotherapy: A Progress in Dendritic Cell, T-Cell, and NK Cell Vaccines. Cells. 2025. doi:10.3390/cells14181453

BibTeX
@article{MasroorAliBeg2025,
  author = {Masroor Ali Beg, Mirza and Aslam, Mohammad and Ayaz, Asma and Akhtar, Muhammad Saeed and Zaman, Wajid},
  title = {Advances in Non-Small Cell Lung Cancer Cellular Immunotherapy: A Progress in Dendritic Cell, T-Cell, and NK Cell Vaccines},
  journal = {Cells},
  year = {2025},
  doi = {10.3390/cells14181453}
}
Kostenlos starten →